BridgeBio Pharma annual debt-to-assets ratio
2018
2019
2020
2021
2022
2023
2024
2025
BridgeBio Pharma Debt-to-Assets Ratio Growth & History (BBIO)
BridgeBio Pharma's debt-to-assets ratio was 2.16 for fiscal 2025.
View full BridgeBio Pharma company overviewBridgeBio Pharma annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.16 | 1.67 | +343.72% |
| 2024 | 2024-12-31 | 0.49 | −0.36 | −42.25% |
| 2023 | 2023-12-31 | 0.84 | 0.12 | +17.25% |
| 2022 | 2022-12-31 | 0.72 | 0.27 | +59.80% |
| 2021 | 2021-12-31 | 0.45 | 0.29 | +176.94% |
| 2020 | 2020-12-31 | 0.16 | 0.00 | +2.61% |
| 2019 | 2019-12-31 | 0.16 | 0.04 | +34.75% |
| 2018 | 2018-12-31 | 0.12 | — | — |
BridgeBio Pharma quarterly debt-to-assets ratio
Q4.18
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.19 | 2.19 | +26813.80% |
| Q1 2026 | 2026-03-31 | 1.95 | 1.94 | +16869.40% |
| Q4 2025 | 2025-12-31 | 2.16 | 1.67 | +343.72% |
| Q3 2025 | 2025-09-30 | 2.02 | 1.35 | +200.68% |
| Q2 2025 | 2025-06-30 | 0.01 | −0.55 | −98.55% |
| Q1 2025 | 2025-03-31 | 0.01 | −0.52 | −97.82% |
| Q4 2024 | 2024-12-31 | 0.49 | −0.36 | −42.25% |
| Q3 2024 | 2024-09-30 | 0.67 | −0.02 | −3.45% |
| Q2 2024 | 2024-06-30 | 0.56 | −0.34 | −37.72% |
| Q1 2024 | 2024-03-31 | 0.53 | −0.19 | −26.95% |
| Q4 2023 | 2023-12-31 | 0.84 | 0.12 | +17.25% |
| Q3 2023 | 2023-09-30 | 0.70 | 0.67 | +2874.44% |
| Q2 2023 | 2023-06-30 | 0.90 | 0.88 | +4092.67% |
| Q1 2023 | 2023-03-31 | 0.72 | 0.16 | +29.21% |
| Q4 2022 | 2022-12-31 | 0.72 | 0.27 | +59.80% |
| Q3 2022 | 2022-09-30 | 0.02 | −0.14 | −85.77% |
| Q2 2022 | 2022-06-30 | 0.02 | −0.10 | −81.62% |
| Q1 2022 | 2022-03-31 | 0.56 | 0.45 | +436.50% |
| Q4 2021 | 2021-12-31 | 0.45 | 0.29 | +176.94% |
| Q3 2021 | 2021-09-30 | 0.16 | 0.03 | +22.99% |
| Q2 2021 | 2021-06-30 | 0.12 | 0.00 | +0.49% |
| Q1 2021 | 2021-03-31 | 0.10 | −0.00 | −0.58% |
| Q4 2020 | 2020-12-31 | 0.16 | 0.00 | +2.61% |
| Q3 2020 | 2020-09-30 | 0.13 | 0.02 | +14.08% |
| Q2 2020 | 2020-06-30 | 0.12 | — | — |
| Q1 2020 | 2020-03-31 | 0.10 | — | — |
| Q4 2019 | 2019-12-31 | 0.16 | 0.04 | +34.75% |
| Q3 2019 | 2019-09-30 | 0.12 | — | — |
| Q4 2018 | 2018-12-31 | 0.12 | — | — |
BridgeBio Pharma debt-to-assets ratio trends
Over the last five fiscal years, BridgeBio Pharma's debt-to-assets ratio increased from 0.16 to 2.16, a change of 1.99. The latest reported quarter, Q2 2026, shows 2.19.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BridgeBio Pharma source filings ↗Community posts
BridgeBio’s Attruby sales expand as a one-time milestone boosts quarterly revenue
BridgeBio ($BBIO) reported third-quarter 2026 revenue of $353.2 million, compared with $120.7 million a year earlier. US Attruby sales reached $253.2 million, increasing approximately $31 million sequentially and $145 million year over year ...
